Interleukin-6 Kit

Brand

GENWAY

Overview

Intended Use: Immunoenzymetric assay for the in vitro quantitative measurement of human interleukin-6 (IL-6) in serum. Background: A. Biological activitiesHuman Interleukin 6 (IL-6) is a 184 A. A. polypeptide with potential O and N-glycosylation sites and a significant homology with G-CSF. It is produced by various cells including T- and B-cells monocytes fibroblasts keratinocytes endothelial cells mesangial cells astrocytes bone marrow stroma cells and several tumor cells. It regulates the growth and differentiation of various cell types with major activities on the immune system hematopoïesis and inflammation. These multiple actions are integrated within a complex cytokine network where several cytokines induce (IL-1 TNF PDGF IFNs . . . ) or are induced by IL-6 and the final effects result from either synergistic or antagonistic activities between IL-6 and the other cytokines (IL-1 IL-2 IL-4 IL-5 IFN¬ IL-3 GM-CSF M-CSF CSF . . . ). IL-6 induces final maturation of Bcells into antibody producing cells and is a potent growth factor for myeloma/plasmacytoma cells. It (co-) stimulates T-cell growth and cytotoxic T-cell differentiation. It promotes megakaryocyte development and synergizes with other cytokines to stimulate multipotent hematopoïetic progenitors. It can also induce differentiation and growth inhibition of some leukemia -or non hematopoïetic tumoral cell lines. IL-6 is also a major inducer of the acute phase reactions in response to inflammation or tissue injury. Along with IL-1 and TNF it induces the synthesis of acute phase proteins (APP) by hepatocytes each cytokine or combination of cytokines showing a preferential pattern of APP production. IL-6 also interacts with the neuroendocrine system e. g. by inducing ACTH production. Thus IL-6 is a pleiotropic cytokine with multiple endocrine paracrine and possibly autocrine activities in various tissues. Principles of the method: The IL-6-EASIA is a solid phase Enzyme Amplified Sensitivity Immunoassay performed on microtiterplate. The assay uses monoclonal antibodies (MAbs) directed against distinct epitopes of IL-6. Calibrators and samples react with the capture monoclonal antibody (MAb 1) coated on microtiter well and with a monoclonal antibody (MAb 2) labelled with horseradish peroxidase (HRP). After an incubation period allowing the formation of a sandwich: coated MAb 1 - human IL-6 - MAb 2 - HRP the microtiterplate is washed to remove unbound enzyme labelled antibody. Bound enzymelabelled antibody is measured through a chromogenic reaction. Chromogenic solution (TMB) is added and incubated. The reaction is stopped with the addition of Stop Solution and the microtiterplate is then read at the appropriate wavelength. The amount of substrate turnover is determined colourimetrically by measuring the absorbance which is proportional to the IL-6 concentration. A calibration curve is plotted and IL-6 concentration in samples is determined by interpolation from the calibration curve. The use of the EASIA reader (linearity up to 3 OD units) and a sophisticated data reduction method (polychromatic data reduction) result in a high sensitivity in the low range and in an extended calibration range. Storage and Stability: ? Before opening or reconstitution all kits components are stable until the expiry date indicated on the vial label if kept at 2 to 8C. ? Unused strips must be stored at 2-8C in a sealed bag containing a desiccant until expiration date. ? After reconstitution calibrators controls and specimen Diluent are stable for 4 days at 2 to 8C. For longer storage periods aliquots should be made and kept at -20C for maximum 2 months. Avoid successive freeze thaw cycles. ? The concentrated Wash Solution is stable at room temperature until expiration date. ? Freshly prepared WorkingWash solution should be used on the same day. ? After its first use the conjugate is stable until expiry date if kept in the original well-closed vial at 2 to 8C. ? Alterations in physical appearance of kit reagents may indicate instability or deterioration. Sensitivity and Specificity: No significant cross-reaction was observed in presence of 50 ng of IL-1\" IL-1# IL-2 IL-3 IL-4 IL-7 IL-8 IL-10 GM-CSF IFN-\" IFN- LIF MIP-1\" MIP- 1# MCP-1 OSM RANTES TGF-# TNF-\" and TNF-#. A very tenuous crossreaction (0. 06%) is observed with G-CSF. Product Name: Interleukin-6 Function: IL-6 is a cytokine with a wide variety of biological functions: it plays an essential role in the final differentiation of B-cells into Ig-secreting cells it induces myeloma and plasmacytoma growth it induces nerve cells differentiation in hepatocytes it induces acute phase reactants. Subcellular Location: Secreted. Ptm: N- and O-glycosylated. Polymorphism: Genetic variations in IL6 may be correlated with bone mineral density (BMD). Low BMD is a risk factor for osteoporotic fracture. Osteoporosis is characterized by reduced bone mineral density disrutption of bone microarchitecture and the alteration of the amount and variety of non-collagenous proteins in bone. Osteoporotic bones are more at risk of fracture. Disease: Genetic variations in IL6 are associated with susceptibility to systemic juvenile rheumatoid arthritis [MIM:604302]. Systemic juvenile rheumatoid arthritis is juvenile chronic arthritis associated with severe debilitating extraarticular features and occasionally fatal complications. Despite medical treatment many children still experience early joint destruction necessitating surgical replacement. Disease: At least 1 polymorphism in the IL6 gene renders HIV-infected men susceptible to Kaposi sarcoma [MIM:148000]. Kaposi sarcoma is a sarcoma of spindle cells mixed with angiomatous tissue. A relatively rare malignant skin tumor that results in multifocal purplish coloured papules or plaques that eventually form nodules. Most commonly seen in patients who suffer from AIDS. Similarity: Belongs to the IL-6 superfamily.

spezie

other

detection target

Interleukin-6

pack size

96 tests